STOCK TITAN

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units to six new employees as part of their employment compensation. The awards, made under the Nasdaq inducement grant exception, include 8,090 shares of common stock and 8,290 RSUs. The stock options have an exercise price of $25.32 per share and a 10-year term, vesting over four years. The RSUs also vest over four years, with 25% vesting annually, subject to continued service with the company.
PTC Therapeutics, Inc. ha annunciato l'approvazione di opzioni su azioni non-statutarie e unità azionarie vincolate per sei nuovi dipendenti come parte della loro remunerazione lavorativa. I premi, concessi tramite l'eccezione di concessione di incentivi della Nasdaq, includono 8.090 azioni ordinarie e 8.290 RSU. Le opzioni su azioni hanno un prezzo di esercizio di 25,32 dollari per azione e una durata di 10 anni, con maturazione ripartita su quattro anni. Le RSU maturano anch'esse in quattro anni, con il 25% che si concretizza annualmente, a condizione di continuare il servizio con l'azienda.
PTC Therapeutics, Inc. anunció la aprobación de opciones sobre acciones no estatutarias y unidades de acciones restringidas para seis nuevos empleados como parte de su compensación laboral. Los premios, realizados bajo la excepción de concesión de incentivos de Nasdaq, incluyen 8,090 acciones comunes y 8,290 URAs. Las opciones sobre acciones tienen un precio de ejercicio de $25.32 por acción y un término de 10 años, con una adquisición de derechos progresiva a lo largo de cuatro años. Las URAs también se adquieren durante cuatro años, con un 25% que se adquiere anualmente, sujeto a la continuidad del servicio en la empresa.
PTC 테라퓨틱스, Inc.는 새로운 직원 6명에게 스톡 옵션(비법정)과 제한적 주식 단위를 부여하는 것을 승인했다고 발표했습니다. 이 상은 나스닥 유인 부여 예외를 통해 이루어졌으며, 8,090주의 보통주와 8,290주의 RSU를 포함합니다. 스톡 옵션은 주당 $25.32의 행사 가격과 10년의 기간을 가지며, 4년에 걸쳐 권리가 확정됩니다. RSU도 4년에 걸쳐 확정되며, 매년 25%씩, 회사에서 지속적인 서비스를 제공하는 조건하에 확정됩니다.
PTC Therapeutics, Inc. a annoncé l'approbation d'options d'achat d'actions non statutaires et d'unités d'actions restreintes pour six nouveaux employés, faisant partie de leur rémunération. Les attributions, effectuées sous l'exception de subvention d'incitation du Nasdaq, comprennent 8 090 actions ordinaires et 8 290 RSU. Les options d'achat d'actions ont un prix d'exercice de 25,32 $ par action et une durée de 10 ans, avec une acquisition échelonnée sur quatre ans. Les RSU s'acquièrent également sur quatre ans, avec 25 % acquis chaque année, sous réserve de la poursuite du service auprès de l'entreprise.
PTC Therapeutics, Inc. hat die Genehmigung von nicht-statutarischen Aktienoptionen und Restricted Stock Units für sechs neue Mitarbeiter als Teil ihrer Beschäftigungsvergütung bekanntgegeben. Die Zuweisungen, die unter der Nasdaq-Anreizzuweisungsausnahme gemacht wurden, umfassen 8.090 Stammaktien und 8.290 RSUs. Die Aktienoptionen haben einen Ausübungspreis von $25,32 pro Aktie und eine Laufzeit von 10 Jahren, wobei die Vesting über vier Jahre erfolgt. Auch die RSUs vesten über vier Jahre mit einer jährlichen Vesting-Rate von 25%, vorbehaltlich der fortgesetzten Dienstleistung im Unternehmen.
Positive
  • None.
Negative
  • None.

WARREN, N.J., April 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an aggregate of 8,090 shares of its common stock and 8,290 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to six new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on April 19, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $25.32 per share, the closing price of PTC's common stock on April 19, 2024, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn. 

For more information please contact:

Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

Cision View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302125159.html

SOURCE PTC Therapeutics, Inc.

FAQ

What did PTC Therapeutics announce regarding inducement grants?

PTC Therapeutics announced the approval of non-statutory stock options and restricted stock units for six new employees as part of their employment compensation.

How many shares of common stock and RSUs were granted to the new employees?

The new employees were granted 8,090 shares of common stock and 8,290 restricted stock units (RSUs) by PTC Therapeutics.

What is the exercise price per share for the stock options granted?

The exercise price per share for the stock options granted by PTC Therapeutics is $25.32.

How long is the term for the stock options granted by PTC Therapeutics?

The stock options granted by PTC Therapeutics have a 10-year term.

How do the stock options and RSUs vest for the new employees?

The stock options vest over four years, with 25% vesting on the first anniversary and 6.25% every three months thereafter. The RSUs also vest over four years, with 25% vesting annually.

PTC Therapeutics, Inc.

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Stock Data

2.58B
56.48M
2.79%
112.93%
13.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH PLAINFIELD

About PTCT

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.